Athersys

Athersys EV/EBITDA

Delisted·Oct 1, 2026

EV/EBITDA (Enterprise Value to EBITDA) of Athersys (ATHXQ) as of Nov 20, 2026.

EV/EBITDA

-0.00

YoY

13.28%

Last updated:

EV/EBITDA (Enterprise Value to EBITDA) of Athersys is 2022 -0.00 . EV/EBITDA (Enterprise Value to EBITDA) of Athersys was 2021 -0.00 . It decreases by 13.28% lower compared to the previous year.

The Athersys EV/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBITDA
Date
EV/EBITDA
Jan 1, 2015
1.35 USD
Jan 1, 2016
0.96 USD
Jan 1, 2017
0.90 USD
Jan 1, 2018
2.06 USD
Jan 1, 2019
-0.00 USD
Jan 1, 2020
-0.00 USD
Jan 1, 2021
-0.00 USD
Jan 1, 2022
-0.00 USD
The Athersys EV/EBITDA history
YEAREV/EBITDAYoY
-0.00+13.28%
-0.00-9.56%
-0.00-42.17%
-0.00-100.00%
2.06+128.83%
0.90-6.52%
0.96-28.81%
1.35+49.21%
0.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys, Inc. generates revenue through the development and commercialization of its MultiStem (invimestrocel) cell therapy, an allogeneic stem cell product candidate derived from adult bone marrow. The company focuses on late-stage clinical development for critical care, neurological conditions, inflammatory disorders, pulmonary conditions, and cardiovascular disease. Its lead product, MultiStem, is currently in Phase III clinical trials for ischemic stroke under the MASTERS-2 study. Athersys targets medical institutions and healthcare providers seeking innovative treatments for unmet medical needs in multiple disease areas. The company's primary product, MultiStem, is manufactured from human stem cells obtained from adult bone marrow and alternative tissue sources. It is designed to address conditions including critical care indications, neurological disorders, inflammatory and immune disorders, pulmonary conditions, and cardiovascular disease. Athersys conducts Phase III trials for ischemic stroke treatment, aiming to secure regulatory approval for broader market access. Revenue streams are expected to emerge post-approval through therapeutic product sales to hospitals and clinics. Athersys, Inc. operates in the biotechnology sector with a focus on regenerative medicine, leveraging its MultiStem platform to address unmet medical needs. The company's clinical development strategy centers on late-stage trials for ischemic stroke and other conditions, targeting healthcare providers and medical institutions as key customers. Commercialization of MultiStem will likely involve partnerships with healthcare systems for treatment protocols and patient access. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

On Eulerpool you can find the complete historical development of EV/EBITDA (Enterprise Value to EBITDA) Athersys since 2006 – with annual values, charts, and detailed analysis.

The EV/EBITDA ratio is a widely used valuation metric that compares a company's enterprise value to its EBITDA. It normalizes for differences in capital structure, taxation, and depreciation policies.

To evaluate EV/EBITDA (Enterprise Value to EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBITDA (Enterprise Value to EBITDA).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBITDA (Enterprise Value to EBITDA)'s Athersys with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Athersys

All Key Metrics — Athersys